Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Hepatitis C

New hepatitis C combination treatment effective in HIV coinfected patients

Patients with both hepatitis C virus and HIV responded well to daclatasvir combined with sofosbuvir in a study.

New hepatitis C combination treatment effective in HIV connected patients. In the image, micrograph of a T cell infected by numerous, spheroid-shaped, mustard-colored human immunodeficiency virus (HIV) particles

Source: National Institute of Allergy and Infectious Diseases (NIAID)

Infection with HIV (pictured), concurrently with hepatitis C virus, can speed up the onset of liver disease 

Worldwide, hepatitis C virus (HCV) infection affects up to a quarter of people with HIV type 1 (HIV-1), accelerating the onset of liver disease. Now, results of an open-label study suggest that treatment with the NS5A inhibitor daclatasvir, together with the NS5B inhibitor sofosbuvir, is effective against HCV in HIV-coinfected patients.

The ALLY-2 trial, funded by Bristol-Myers Squibb and published in The New England Journal of Medicine (online, 21 July 2015[1]), involved 151 previously untreated patients with HCV genotypes 1–4 and HIV-1 infection who were given daclatasvir 60mg plus sofosbuvir 400mg daily for either 8 weeks or 12 weeks. The study also involved 52 previously treated patients who were given 12 weeks of therapy at the same doses.

In treatment-naïve patients, sustained virologic response (SVR) rates for HCV were 97.0% with 12 weeks’ treatment and 76.0% with 8 weeks’ treatment. In previously treated patients, SVR was 98.1% after 12 weeks.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069093

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.